Prostate Cancer Trial, Recruiting NCT07432360 Sponsor: Virdx, Inc. Condition: Prostate Cancer
Back to Prostate Cancer

Prostate Cancer Trial, Recruiting

NCT07432360
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who have a prostate and are 18 years of age or older.
  • People who have been diagnosed with prostate cancer through a biopsy and are scheduled to have their prostate surgically removed.
  • People who have read and signed a consent form showing they understand what the study involves and why it is being done.
  • People who are willing, able, and legally permitted to take part in the study.
  • People who are able to follow the specific rules and restrictions set out in the study plan.

Who may not be able to join:

  • People who are not able to give consent to participate.
  • People who have previously received hormone treatments for prostate cancer, such as androgen deprivation therapy or 5-alpha-reductase inhibitors.
  • People who have previously received any treatment for prostate cancer.
  • People who have previously had a surgical procedure on the prostate, including a transurethral resection of the prostate (a procedure to remove prostate tissue through the urethra).
  • People who have previously had hip replacement surgery on one or both sides, or who have other metal implants in the hip area that would interfere with MRI scanning.
  • People who cannot have an MRI scan for general medical reasons, such as having a pacemaker or certain metal implants in the body.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 19 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marcelo Araujo Queiroz, MD PhD, Instituto do Câncer do Estado de São Paulo

Phone: +4917680891277

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Virdx, Inc.
Registry
ClinicalTrials.gov
Start date
28 January 2026
Est. completion
1 June 2028

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Comparison of different microstructure models in the performance of detecting csPCa

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov